Alexis Ogdie, MD, MSCE

Dr. Ogdie’s research is focused on inflammatory arthritis (IA) including psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and rheumatoid arthritis (RA). The mission of her research program is to improve outcomes in IA by accelerating diagnosis, increasing the focus on meaningful, patient-centered outcomes, and developing and advancing methods for precision medicine.

Dr. Ogdie is an expert in the care of patients with IA, Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program, and Director of the Penn Center for Clinical Epidemiology and Biostatistics. Her areas of expertise include epidemiology and pharmacoepidemiology, biostatistical methods for observational studies (e.g., complex time to event modeling, prediction modeling), outcome measures (e.g., qualitative and quantitative/psychometric assessment), clinical trial design, and more general qualitative methods (e.g., survey, focus group and interview studies).

Her recent work has focused on a) pragmatic trial design and implementation including the recent launch of a first head-to-head pragmatic trial in PsA (EVOLUTION, NCT05669833); b) trials aimed at improving outcomes in PsA through holistic care including a trial to test Dietary Interventions in PsA (DIPSA, NCT04180904), and a new single arm trial to address whole patient care as a novel care paradigm in rheumatology (funded by a Rheumatology Research Foundation); and c) identifying risk factors for development of PsA among patients with psoriasis.